Aurobindo Pharma (NSE: AUROPHARMA) Shares Slip Despite US FTC Approval for $250 Million Lannett Acquisition

Aurobindo Pharma shares edged lower on June 22, 2026, despite a significant regulatory win announced before market open. Aurobindo Pharma USA, a wholly-owned subsidiary, received approval from the US Federal Trade Commission to proceed with the $250 million acquisition of Lannett Company LLC on a cash-free, debt-free basis. It inclusive of normalized working capital, with the deal expected to close before the end of June 2026. 

The stock traded at ₹1,504.30 on June 22, 2026, within a day’s range of ₹1,494.40 to ₹1,511.00, against a 52-week high of ₹1,550.00 and a low of ₹1,016.10. Peer pharma stocks including Sun Pharmaceutical (NSE: SUNPHARMA) and Cipla (NSE: CIPLA) also traded mixed on the day.

FTC Green Light: What the Lannett Deal Covers

Lannett is a Pennsylvania-based generic pharmaceutical company specializing in the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The deal gives Aurobindo Pharma direct access to a critical US product segment.

Key deal details:

• Deal value: $250 million (cash-free, debt-free basis)
• Target: Lannett Company LLC (100% stake)
• Agreement signed: July 2025
• FTC approval received: June 19, 2026
• Expected closing: Before the end of June 2026
• Manufacturing site: Seymour, Indiana

The Lannett manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA’s domestic manufacturing footprint and aligning with US policy priorities around supply chain resilience.

#NDTVProfitExclusive | Aurobindo had to divest products to close its US deal.

But was this a setback or already priced in? Here’s why the company still sees strong upside.

CEO Swami Iyer explains the Lanett deal dynamics in conversation with @niraj_shah pic.twitter.com/VUh1rkkkKj

— NDTV Profit (@NDTVProfitIndia) June 22, 2026

The FTC Divestiture Condition

The approval did not come without conditions, and that detail matters for understanding the full picture.

The FTC required Aurobindo to divest four generic drug products to New Jersey-based Quagen Pharmaceuticals, resolving anticompetitive concerns in markets where combining the two companies would reduce competition to a limited number of players.

The FTC stated that “Aurobindo’s acquisition of Lannett would combine two of a limited number of competitors in the markets for four different generic pharmaceutical products that provide critical relief for patients.” The divestiture was the price of approval. 

Aurobindo Pharma: Stock Metrics on June 22

The mild pullback on June 22 followed a 3.75% rally on June 19, the day FTC approval first broke.

Key stock data as of June 22, 2026:

• NSE price: ₹1,504.30
• Previous close: ₹1,497.80
• Market cap: ₹86,992.47 crore
• PE ratio: 36.02
• PB ratio: 3.82
• Mutual fund shareholding: 17.79%
• 52-week high: ₹1,550.00 (May 21, 2026)
• 52-week low: ₹1,016.10 (January 27, 2026)

Aurobindo Pharma shares are up 26% in 2026, compared with an 8% rise in the Nifty Pharma index during the same period.

Strategic Rationale Behind the Acquisition

The transaction is expected to be immediately accretive to Aurobindo Group’s earnings per share, and is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages.

Shares of Aurobindo Pharma have delivered more than 57% returns over the last five years, over 123% gains over the last three years, and more than 36% returns over the past one-year period. The Lannett acquisition builds on this trajectory by adding ADHD-segment products and US manufacturing scale. Peers Dr. Reddy’s Laboratories (NSE: DRREDDY) and Zydus Lifesciences (NSE: ZYDUSLIFE) remain active in similar US generics consolidation plays.

Conclusion

Aurobindo Pharma’s modest slip on June 22, 2026, reads as post-event consolidation rather than a rejection of the Lannett deal’s strategic logic. The $250 million acquisition, cleared by the US FTC with a four-drug divestiture condition. It adds 4 billion annual dose capacity, US manufacturing scale, and access to complex generic segments. With closing expected before June 30, 2026, and the deal immediately accretive to EPS, Aurobindo Pharma’s US footprint is set to grow in a material and measurable way.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.